Table 1.
The characteristics of the total participants and patients with or without CKD
| Total (N = 2484) |
CKD (−) (N = 1937) |
CKD (+) (N = 547) |
p | |
|---|---|---|---|---|
| Age (year) | 65.12 ± 12.71 | 64.28 ± 12.53 | 68.09 ± 12.94 | < 0.01 |
| Male (%) | 55.9% | 57.9% | 49.0% | < 0.01 |
| Systolic BP (mmHg) | 142.30 ± 17.68 | 142.15 ± 17.64 | 142.81 ± 17.81 | 0.44 |
| Diastolic BP (mmHg) | 83.01 ± 11.93 | 82.92 ± 12.09 | 83.35 ± 11.34 | 0.45 |
| Hypertension grades (%) | 0.16 | |||
| Controlled | 41.6% | 42.8% | 37.5% | |
| 1 | 36.9% | 36.3% | 39.0% | |
| 2 | 14.9% | 14.4% | 16.5% | |
| 3 | 6.7% | 6.6% | 7.0% | |
| Antihypertensive therapy (%) | 90.7% | 90.7% | 90.7% | 0.99 |
| TG (mmol/L) | 1.62(1.14, 2.3) | 1.60(1.11–2.26) | 1.77(1.28–2.42) | < 0.01 |
| Elevated TG (%) | 46.9% | 45.2% | 54.1% | 0.01 |
| HDL-C (mmol/L) | 1.21(1.01–1.48) | 1.21(1.02–1.46) | 1.2(0.99–1.53) | 0.90 |
| Reduced HDL-C (%) | 40.1% | 39.5% | 42.5% | 0.35 |
| Statin (%) | 60.3% | 58.2% | 67.1% | < 0.01 |
| FBG (mmol/L) | 6.38 ± 2.14 | 6.31 ± 2.01 | 6.72 ± 2.62 | 0.01 |
| Elevated FBG (%) | 58.3% | 56.6% | 66.1% | 0.01 |
| Diabetes (%) | 24.7% | 23.7% | 28.3% | 0.03 |
| Antidiabetic therapy (%) | 24.2% | 22.8% | 29.2% | < 0.01 |
| Waist circumference (cm) | 84.18 ± 14.75 | 83.71 ± 13.89 | 85.86 ± 17.35 | < 0.01 |
| Elevated waist circumference (%) | 47.5% | 45.7% | 54.0% | < 0.01 |
| eGFR (ml/min/1.73 m2) | 79.24 ± 29.18 | 91.16 ± 18.87 | 37.03 ± 17.91 | < 0.01 |
| CKD | 22.0% | – | – | – |
BP: Blood pressure; CKD: Chronic kidney disease; eGFR: estimated glomerular filtration rate; FBG: Fasting blood glucose; HDL-C: High density lipoprotein-C; TG: Triglycerides;